Loading...
The RADAR Study: Week 48 Safety and Efficacy of RAltegravir Combined with Boosted DARunavir Compared to Tenofovir/Emtricitabine Combined with Boosted Darunavir in Antiretroviral-Naive Patients. Impact on Bone Health
BACKGROUND: NRTI-sparing regimens may avoid long-term mitochondrial, bone and renal toxicities and maintain viral suppression. METHODS: In the RADAR study, 85 antiretroviral-naïve HIV-infected patients were randomized to receive either raltegravir (RAL) (n = 42) or tenofovir/emtricitabine (TDF/FTC)...
Na minha lista:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Public Library of Science
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4149560/ https://ncbi.nlm.nih.gov/pubmed/25170938 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0106221 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|